Increased overall survival and a longer time before tumor recurrence is associated with low presurgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer (NSCLC). Patients with high uptake of labeled glucose may benefit from additional therapy following surgery. {read more here}